Editor’s Note: Patient Worthy is honored to share this story submitted to us by Regina Portnoy, a clinical researcher with over 20 years of experience.
Editor’s Note: Patient Worthy is honored to share this patient story from our friends at Elephants & Tea. To see the story in its original
As shared on drugs.com, Vascarta Inc. has reported encouraging results from a Phase 1b clinical study evaluating its investigational topical/transdermal curcumin gel, VAS-101, for the
Editor’s Note: Patient Worthy is honored to share this article from our friends at the Brighter Hope Foundation. To see the article in its original
Labcorp announced the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer
As reported on drugs.com, Revolution Medicines has reported practice-changing efficacy results from a pivotal Phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic ductal
This, year the PCBers will meet in Indianapolis, Indiana. They will be celebrating 30 years as a community, as well as celebrating a much brighter
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the
As reported on Business Wire, Enveda, a clinical-stage biotechnology company focused on discovering novel small-molecule medicines, has reported encouraging results from a Phase 1b study
A recent article from Inside Precision Medicine states: For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into
AstraZeneca has announced positive results from the pivotal phase III MIRANDA trial of tozorakimab, a groundbreaking first-in-class monoclonal antibody designed to treat Chronic Obstructive Pulmonary
On January 20, 2014, at 54 years old, I experienced what I casually called an “anxiety numbness event.” My left thumb and index finger went
The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating
My story began very suddenly on May 4th, 2025, when I was home from graduate school visiting my family. It had been a great day,
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and remains one of the most difficult cancers to treat. Characterized by aggressive
WebMD published a story about a young woman, Maddie, who had spent nine years in wheelchair confinement resulting from a rare metabolic disease related to
Health Canada has officially approved Cysklar® (cysteamine ophthalmic solution) 0.44%, marking a significant breakthrough for Canadians living with cystinosis. According to BusinessWire.com, the approval enables
Putting feelings into words does more than help you reflect. Brain imaging research shows it can shift activity inside emotional circuits. If you are someone
💙 Brain Tumor Awareness Month
This month, we pause to honor the strength, resilience, and courage of every individual and family impacted by brain tumors. Behind every diagnosis is a story of perseverance, hope, and unwavering determination.
To those navigating this journey, you are not alone. Your strength inspires, your stories matter, and your voices help bring light to a condition that too often goes unseen. To caregivers, loved ones, and advocates, your compassion and support make a profound difference every single day.
May this month serve as a reminder to lead with empathy, to listen with understanding, and to stand together in support. Through awareness, education, and continued advocacy, we move closer to a future filled with better treatments, stronger support systems, and lasting hope.
#BrainTumorAwarenessMonth #caregiversupport #cancerawareness #PatientWorthy
Huntington’s disease is more than a diagnosis; it is a life‑altering inherited condition that affects entire families and future generations. Because each child of an affected parent has a 50% chance of inheriting the gene, it is important to understand the risks and make informed decisions. Learning about Huntington’s can also help people recognize early signs such as changes in movement, thinking, or mood, which can lead to earlier support and care planning. Education helps reduce stigma since the disease impacts both physical and cognitive health in ways that are often misunderstood. While there is currently no cure, increasing awareness can support families, strengthen advocacy efforts, and help move research forward. 💙
If you'd like to share your story with Huntington's Disease, click here: bit.ly/4dV7gru
#HuntingtonsDisease #RareDiseaseAwareness #BrainHealth #PatientWorthy #ShareYourStory
Every May, Bladder Cancer Awareness Month shines a light on a cancer that is often overlooked, misunderstood, or mistaken for something else. Bladder cancer affects more than 610,000 people worldwide each year, and over 1.9 million people are currently living with the disease. Yet awareness remains low, and symptoms are too often ignored or misinterpreted.
Bladder cancer is more common in men, but women are often diagnosed later because symptoms are mistaken for infections or age-related changes. Early diagnosis makes a real difference. When bladder cancer is detected early, treatment is highly effective and survival rates can reach up to 90%. Recognizing symptoms and acting quickly can save lives. (Source: WorldBladderCancer .org)
Help raise awareness and share your bladder cancer story with us here: bit.ly/4dV7gru
#BladderCancerAwarenessMonth #bladdercancer #PatientWorthy
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
